Pancreatic Cancer

P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=8000, Recruiting, UMC Utrecht | Trial completion date: May 2025 --> Aug 2030 | Trial primary completion date: Feb 2024 --> Feb 2030

P=N/A, N=50, Recruiting, University of Oklahoma | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

Thus, conservative management with close surveillance may be feasible for carefully selected patients with small, asymptomatic tumors. However, additional cases are needed to clarify optimal management strategies.

Moreover, in patient-derived primary cells, accelerated PTK7 kinetics positively correlate with invasive and metastatic phenotypes, confirming the clinical relevance of this biophysical regulatory mechanism. This work establishes pseudokinase spatial dynamics as a biophysical regulator of tumor progression, revealing a non-catalytic paradigm where receptor diffusion kinetics encode cellular behavior through stochastic signaling potentiation.

P=N/A, N=20, Not yet recruiting, Huazhong University of Science and Technology

P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting

P1/2, N=52, Recruiting, Bold Therapeutics Inc. | N=38 --> 52

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

This study reports AGP regimen as a promising therapeutic modality for PDAC, and provides a detailed mechanism by which a STING-mediated signaling relay from PDAC tumor cells to TAMs boost antitumor immunity and contribute to AGP chemotherapy efficacy. Furthermore, STING expression in tumor tissues correlated with improved prognosis, highlighting its potential as a predictive biomarker and promising therapeutic target.

These findings indicate that NVA induces NO-dependent, caspase-independent cell death, distinct from classical apoptosis. The present study provides fundamental insights into the potential use of VA-based NO donors as antitumor agents against pancreatic cancer.